This week in the Beyond the Basics/Treatment section of our website, we’ve posted an article about some ongoing promising immunological research in CLL with the agent CC-122. While much of the recent excitement, for very good reasons, has been about the new class of drugs that block the B-cell receptor such as ibrutinib and idelalisib, or the fresh approval of venetoclax that inhibits BCL-2 leading to programmed cell death, there is still a need for more and Celgene has led the way with a different and important approach, namely drugs that tweak our disrupted immune system such as lenalidomide and now CC-122. You can read my commentary and read about the research that is ongoing here. [ cllsociety.org/2016/05/cc-1... ]
I suspect immune therapies will be needed to seal the deal for many of us. Now that research with lenalidomide in CLL is slowing down, trials with CC-122 may be part of our future.
The full article and the alert with news of some upcoming patient meetings is on the website.
We are all in this together.